New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 5 #12 September, 2000

State-of-the-Art in the Management of Cancer

BLADDER CANCER-PART I

ETIOLOGY, EPIDEMIOLOGY, AND TUMOR MARKERS

Etiology

  • Tobacco Smoking
  • Environmental and Occupational Exposure
  • Lifestyle Factors
  • Health Factors

Pathogenesis

Epidemiology

  • Global Incidence and Mortality
  • USA Incidence
    • Gender
    • Age
  • USA Prevalence

Tumor Markers

Technology Update

SYNTHETIC NUCLEIC ACID SEQUENCE-SPECIFIC CONSTURCTS AS ONCOLOGY THERAPEUTICS - PART 1

Mechanism of Action

Desirable Attributes of Synthetic Nucleic Acid Sequences as Therapeutics

  • Sequence Structure and Length
  • Backbone Modifications and Consequences
    • Phosphorothioate (P=S) ODN
    • Methylphosphonate (M=P) ODN
    • N3’-P5’ phosphoramidate (P=A) ODN
    • Mixed-backbone ODN (MBO)
    • Morpholino ODN
    • Peptide nucleic acid (PNA) linkage ODN
    • Locked nucleic acid (LNA) ODN
  • Delivery Strategies and Entry into Cells
    • Virus-mediated transfer
    • Attachment of lipophilic groups
    • Fusogenic peptides
    • Phenoxazine-modified ODN
    • Streptolysin O
    • Electroporation
    • Microinjection
    • Scrape-loading
    • Osmotic-loading or osmotic-lysis
    • Syringe-medicated loading
    • Hormone Carriers
    • Spherulites
    • Cationic lipid facilitators (lipids and liposomes)
    • Starburst polyamidoamine (PAMAM) dendrimers
    • Copolymers
    • Amphiphiles
    • Porphyrins
    • Carrier-ligand conjugates
    • Controlled-release carriers
    • Virosomes

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887